Primary Biliary Cholangitis (PBC), also known as Primary Biliary Cirrhosis, is a chronic liver disease that primarily affects the small bile ducts within the liver. It is an autoimmune condition, meaning that the body's immune system mistakenly attacks the bile ducts, leading to their inflammation and damage over time.
PBC is characterized by a gradual destruction of the bile ducts, which results in impaired bile flow. Bile is a substance produced by the liver that helps in the digestion and absorption of fats. When the bile ducts become damaged, bile accumulates in the liver, leading to liver cell damage and scarring, known as cirrhosis.
Although the exact cause of PBC is unknown, it is believed to involve a combination of genetic and environmental factors. It predominantly affects middle-aged women, but can also occur in men and people of all ages.
Common symptoms of PBC include fatigue, itching, dry eyes and mouth, jaundice (yellowing of the skin and eyes), and abdominal pain. However, some individuals may not experience any symptoms in the early stages of the disease.
Early diagnosis of PBC is crucial to prevent further liver damage. Blood tests that measure liver function and specific antibodies associated with PBC are commonly used for diagnosis. Additionally, imaging tests such as ultrasound or magnetic resonance cholangiopancreatography (MRCP) may be performed to assess the extent of liver damage.
Treatment for PBC aims to slow down the progression of the disease, manage symptoms, and prevent complications. The mainstay of treatment is the use of Ursodeoxycholic acid (UDCA), a medication that helps improve bile flow and reduce liver inflammation. In some cases, additional medications may be prescribed to alleviate symptoms or manage complications.
In advanced stages of PBC, liver transplantation may be considered as a treatment option. Regular monitoring and follow-up with healthcare professionals are essential for individuals with PBC to ensure appropriate management and support.